Preferred Label : abemaciclib;
MeSH synonym : 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amine; 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine;
MeSH hyponym : LY-2835219; LY2385219; LY2835210;
MeSH Related Number : KKT462Q807;
UNII : 60UAB198HK;
Origin ID : C000590451;
UMLS CUI : C3852841;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3601434/fr/verzenios-abemaciclib-cancer-du-sein
2025
false
false
false
France
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
menopause
evaluation of the transparency committee
abemaciclib
breast neoplasms
abemaciclib
breast cancer
Verzenio
neoplasm, malignant
---
https://www.has-sante.fr/jcms/p_3444041/fr/verzenios-abemaciclib-cancer-du-sein-precoce-rh-/her2
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic agents
protein kinase inhibitors
abemaciclib
antineoplastic combined chemotherapy protocols
Adjuvant Therapy
Hormone Receptor-Positive Breast Carcinoma
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative,
node-positive early breast cancer at high risk of recurrence
adult
evaluation of the transparency committee
abemaciclib
breast neoplasms
---
https://www.has-sante.fr/jcms/p_3359071/fr/verzenios-abemaciclib-cancer-du-sein
https://www.has-sante.fr/jcms/p_3359075/fr/decision-n2022-0245/dc/sem-du-13-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-refus-de-la-demande-d-acces-precoce-de-la-specialite-verzenios
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
protein kinase inhibitors
abemaciclib
antineoplastic combined chemotherapy protocols
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative,
node-positive early breast cancer at high risk of recurrence
evaluation of the transparency committee
abemaciclib
breast neoplasms
---
https://www.has-sante.fr/jcms/p_3368269/fr/verzenios-abemaciclib-traitement-adjuvant-du-cancer-du-sein-precoce-avec-rh-positifs
2022
false
false
false
France
treatment outcome
breast neoplasms
antineoplastic combined chemotherapy protocols
Early Stage Breast Carcinoma
chemotherapy, adjuvant
Hormone Receptor-Positive Breast Carcinoma
administration, oral
abemaciclib
antineoplastic agents
protein kinase inhibitors
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
HER2-Negative Breast Carcinoma
evaluation of the transparency committee
abemaciclib
---
https://www.cancer.fr/catalogue-des-publications/inhibiteurs-des-cdk-4-et-6-abemaciclib-palbociclib-ribociclib
2022
false
false
false
France
practice guideline
ribociclib
abemaciclib
ribociclib
palbociclib
palbociclib
abemaciclib
---
https://www.has-sante.fr/jcms/p_3237418/fr/verzenios-abemaciclib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
antineoplastic agents
administration, oral
neoplasm metastasis
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
abemaciclib
aminopyridines
benzimidazoles
---
https://www.has-sante.fr/portail/jcms/c_2892921/fr/verzenios
2019
false
false
false
France
French
treatment outcome
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
neoplasm metastasis
neoplasm recurrence, local
administration, oral
antineoplastic agents
antineoplastic agents
Hormone receptor positive malignant neoplasm of breast (disorder)
insurance, health, reimbursement
evaluation of the transparency committee
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles
---
Verzenios abemaciclib
https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
breast neoplasms
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
abemaciclib
product surveillance, postmarketing
food-drug interactions
drug interactions
pregnancy
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
survival analysis
drug evaluation, preclinical
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles
---